The issues and risks associated with the use of sodium valproate by women of childbearing age are well recognised by medicines regulators and healthcare professionals. Officials in the Department of Health, the HSE, and the Health Products Regulatory Authority are reviewing these issues at present, and considering the next steps that should be taken to minimise the risks involved in the use of this drug. The Minister is aware of requests by patient representative groups for an inquiry into the historical use of sodium valproate in Ireland, and will give further consideration to these requests.